NVO241101C128000
- 0.11
- 0.000.00%
Novo-Nordisk A/S Newsroom
Express News | UK's EMA Says Novo Nordisk Decided Norditropin Nordiflex Will Be Discontinued Entirely; Discontinuation Of Norditropin Nordiflex To Come Into Effect From 2024 End, Timelines May Vary From Country To Country
Unusual Options Activity: NVO, CAH and Others Attract Market Bets, NVO V/OI Ratio Reaches 181.8
Evoke Stock Rockets 90% on Study of Gimoti in GLP-1 Users
Novo Nordisk's Bold Share Repurchase Strategy
Erste Group Initiates Novo-Nordisk A/S(NVO.US) With Hold Rating
Eli Lilly and Co (LLY.US) weight loss drug Mounjaro has been approved in Hong Kong and will be available for sale as early as the end of this year.
eli lilly and co is expected to start selling its popular weight loss drug in Hong Kong as early as the end of this year.
Benzinga Bulls And Bears: Nvidia, Tesla, MicroStrategy, Plug Power — And Crypto Traders Anticipate Dogecoin Topping 50 Cents
Heard on the Street: Pfizer's Activist Battle Might Fizzle -- but Its Stock Probably Won't -- WSJ
Top Gap Ups and Downs on Thursday: WST, TSLA, IBM and More
Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows
Novo Nordisk's Semaglutide Could Also Be Effective Against Alzheimer's
Viking Therapeutics Jumps as Obesity Updates Outshine Q3 Beat
European Equities Traded in the US as American Depositary Receipts Rise Slightly Higher in Thursday Trading
Ozempic May Reduce the Risk of Alzheimer's. That's Huge for Novo Nordisk. -- Barrons.com
Health and Wellness Industry Embraces Surge in Demand for Weight Loss Drugs
Novo Nordisk (NVO.US) is pressuring the FDA in the USA to restrict the generic version of semaglutide, requesting it to be added to the list of drugs with synthesis challenges.
Novo Nordisk (NVO.US) has requested the FDA to include semaglutide in the list of substances that are difficult to synthesize.
Top Gap Ups and Downs on Wednesday: TXN, STLA, MCD and More
Compounded GLP-1s Are a 'Symptom' of Supply Shortage: Ro CEO
Amylyx Upgraded to Buy by BofA on Hypoglycemia Drug Potential
Novo Nordisk to Present New Cardiometabolic and Renal Data, Including With Semaglutide, at Kidney Week 2024, ObesityWeek, The Liver Meeting, and AHA Scientific Sessions 2024